Skip to Content

Arcoxia Approval Status

Arcoxia (etoricoxib) is a selective COX-2 inhibitor for treatment of osteoarthritis.

In April 2007, Merck & Co., Inc. announced the receipt of a Not Approvable Letter from the U.S. Food and Drug Administration (FDA), advising the company that the New Drug Application (NDA) for Arcoxia (etoricoxib) had not been approved.

Development Status and FDA Approval Process for Arcoxia

Apr 27, 2007Merck Receives Non Approvable Letter from FDA for Arcoxia (etoricoxib)
Apr 13, 2007Public Citizen: FDA Should Not Approve "Offspring of Vioxx" Painkiller
Apr 12, 2007FDA Advisory Committee Recommends Against Approval for Merck's NDA for Arcoxia (etoricoxib)
Apr 11, 2007Statement by Merck & Co., Inc. Regarding FDA Arthritis Drugs Advisory Committee Meeting on Arcoxia (etoricoxib)
Apr  9, 2007Arthritis Foundation Chief Public Health Officer Testifies at FDA Hearing on Arcoxia
Nov 10, 2006Merck Responds to FDA-Issued Approvable Letters for Arcoxia (etoricoxib)
Jun 17, 2005Merck Provides Status Update on Ongoing Arcoxia Trials
Oct 29, 2004Merck Receives ’Approvable’ Letter for Arcoxia

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.